Fig. 2: Regorafenib regulates YAP1 activity, phosphorylation, and EMT changes. | Cell Death & Disease

Fig. 2: Regorafenib regulates YAP1 activity, phosphorylation, and EMT changes.

From: Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis

Fig. 2

A Heat map showing YAP1 and p-YAP1 (Ser127) levels in CCA in a reverse-phase protein array (RPPA) database. B Western blot analysis of YAP1 and p-YAP1 (Ser127 and Tyr357) levels in a CCA cell panel. C Western blot analysis of YAP1, p-YAP1 (Tyr357), and EMT-related protein levels in SNU-1196 cells with or without exogenous YAP1 (WT/Y357F). D Q-PCR analysis of EMT-related markers, SNAI2, and vimentin mRNA expression in SNU-1196 cells with or without exogenous YAP1 (WT/Y357F). E Luciferase reporter activity of E-cadherin in HuCCT1 and SNU-1079 cells treated with or without regorafenib. F Luciferase reporter activity of E-cadherin in SNU-1196 cells treated with or without exogenous YAP1 (WT/Y357F). Data are presented as the mean of three independent experiments ± SEM. The significance of the difference was determined using a nonparametric Mann–Whitney U-test. ***p < 0.001.

Back to article page